{"id":"W2900413769","doi":"10.1056/nejmoa1812389","title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6310,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Dapagliflozin; Mace; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Type 2 diabetes; Diabetes mellitus; Stroke (engine); Placebo; Cardiology; Heart failure; Confidence interval; Endocrinology; Percutaneous coronary intervention","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}